tiprankstipranks
Advertisement
Advertisement
Can-Fite Secures Israeli Patent to Bolster Namodenoson Anti-Obesity Franchise
PremiumCompany AnnouncementsCan-Fite Secures Israeli Patent to Bolster Namodenoson Anti-Obesity Franchise
24d ago
Can-Fite BioPharma announces Israeli patent allowance for namodenoson
Premium
The Fly
Can-Fite BioPharma announces Israeli patent allowance for namodenoson
24d ago
Can-Fite BioPharma Shareholders Approve All Proposals at March 10 Special Meeting
Premium
Company Announcements
Can-Fite BioPharma Shareholders Approve All Proposals at March 10 Special Meeting
1M ago
Can-Fite Targets Rare Kidney Disease With New Phase 2 Lowe Syndrome Trial
PremiumCompany AnnouncementsCan-Fite Targets Rare Kidney Disease With New Phase 2 Lowe Syndrome Trial
2M ago
Can-Fite Showcases Namodenoson Anti-Obesity Data in Peer-Reviewed Journal
Premium
Company Announcements
Can-Fite Showcases Namodenoson Anti-Obesity Data in Peer-Reviewed Journal
2M ago
Can-Fite BioPharma announces publication of anti-obesity effect of namodenoson
Premium
The Fly
Can-Fite BioPharma announces publication of anti-obesity effect of namodenoson
2M ago
Can-Fite BioPharma Calls March 3 Special Meeting to Address NYSE Audit Committee Non-Compliance
PremiumCompany AnnouncementsCan-Fite BioPharma Calls March 3 Special Meeting to Address NYSE Audit Committee Non-Compliance
2M ago
Can-Fite Completes Enrollment in Phase 2a Pancreatic Cancer Trial of Namodenoson
Premium
Company Announcements
Can-Fite Completes Enrollment in Phase 2a Pancreatic Cancer Trial of Namodenoson
3M ago
Can-Fite completes patient enrollment in Phase 2a study of Namodenoson
Premium
The Fly
Can-Fite completes patient enrollment in Phase 2a study of Namodenoson
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100